485 results on '"Natoli, Clara"'
Search Results
2. Chemotherapy
3. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
4. Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
5. Chemotherapy
6. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients
7. Correction: Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
8. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study
9. Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients
10. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
11. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
12. Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction
13. Long-term outcome of breast cancer patients with pathologic N3a lymph node stage
14. Supplementary Figure 1 from Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody
15. Supplementary Figure Legend from Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody
16. Supplementary Tables from Interleukin-30 Promotes Breast Cancer Growth and Progression
17. Supplementary Materials and Methods from Interleukin-30 Promotes Breast Cancer Growth and Progression
18. Data from Interleukin-30 Promotes Breast Cancer Growth and Progression
19. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
20. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
21. Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey
22. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer
23. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
24. Tumor-derived microvesicles: The metastasomes
25. Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice
26. Cyclooxygenase-Independent Induction of P2LWAF-1/CIP1, Apoptosis and Differentiation by L-745, 337 and Salicylate in HT-29 Colon Cancer Cells
27. Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
28. Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
29. Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
30. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer
31. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
32. Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice
33. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis
34. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation
35. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
36. sj-docx-1-tam-10.1177_17588359211059873 ��� Supplemental material for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
37. Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer
38. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts
39. Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
40. Additional file 1 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
41. Additional file 2 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
42. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
43. Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A 'snapshot' from clinical practice
44. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
45. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade. The SePHER Study.
46. New Targets for Therapy in Pancreatic Cancer
47. 90K (Mac-2 BP) and galectins in tumor progression and metastasis
48. Viral and Host Factors in Determining Response of Relapsers with Chronic Hepatitis C to Retreatment with Interferon
49. HER2 Nuclear Translocation and Decreased T-DM1 Efficacy in HER2 Positive Advanced Breast Cancer Treated with Dual HER2 Blockade. The SePHER Study.
50. Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.